Honora Englander
Overview
Explore the profile of Honora Englander including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
1675
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams B, Patten A, Peng L, Englander H
J Gen Intern Med
. 2025 Jan;
PMID: 39789272
Background: Hospitalization is a "reachable" moment to engage people in addiction care. Addiction consult services (ACSs) have been shown to improve outcomes for hospitalized patients with substance use disorders (SUDs)....
2.
Shearer R, Englander H, Hagedorn H, Fawole A, Laes J, Titus H, et al.
J Gen Intern Med
. 2024 Nov;
PMID: 39586949
Background: Individuals with opioid use disorder have high rates of hospital admissions, which represent a critical opportunity to engage patients and initiate medications for opioid use disorder (MOUD). However, few...
3.
Krawczyk N, Miller M, Englander H, Rivera B, Schatz D, Chang J, et al.
J Gen Intern Med
. 2024 Oct;
PMID: 39438382
Background: Despite proliferation of acute-care interventions to initiate medications for opioid use disorder (MOUD), significant challenges remain to supporting care continuity following discharge. Research is needed to inform effective hospital...
4.
Bertholet N, Araiedh J, Englander H
Rev Med Suisse
. 2024 Sep;
20(887):1660-1663.
PMID: 39295262
Warnings in Europe signal a rise in illicitly-manufactured fentanyl and other high potency synthetic opioids which could destabilize drug markets, strain health systems, and escalate harms of substance use and...
5.
Shearer R, Hagedorn H, Englander H, Siegler T, Kibben R, Fawole A, et al.
J Subst Use Addict Treat
. 2024 Sep;
167():209520.
PMID: 39265915
Introduction: Methadone and buprenorphine are effective treatment for opioid use disorder (OUD), yet they are vastly under-utilized across US hospitals. To inform a national trial assessing the effectiveness of implementation...
6.
U.S. trends in methamphetamine-involved psychiatric hospitalizations in the United States, 2015-2019
Calcaterra S, Yamkovoy K, Swathi P, Ciccarone D, Del Pozo B, Englander H, et al.
Drug Alcohol Depend
. 2024 Aug;
262:111409.
PMID: 39089187
Background: In the U.S., overdose deaths and substance treatment admissions related to methamphetamine are rising. This study aims to measure and compare U.S. temporal trends in methamphetamine-involved psychiatric hospitalizations. Methods:...
7.
8.
9.
Englander H, Chappuy M, Krawczyck N, Bratberg J, Potee R, Jauffret-Roustide M, et al.
Int J Drug Policy
. 2024 Jun;
129:104487.
PMID: 38878588
Despite being among the most effective treatments for opioid use disorder, methadone is largely unavailable in the United States, due primarily to federal and other policies that limit its availability...
10.
Liu P, Chan B, Sokolski E, Patten A, Englander H
J Addict Med
. 2024 Jun;
18(4):458-462.
PMID: 38832695
Objectives: Treating acute opioid withdrawal and offering medications for opioid use disorder (OUD) is critical. Hospitalization offers a unique opportunity to rapidly initiate methadone for OUD; however, little clinical guidance...